Table 2.
Plasma concentrations of endothelin-1 (ET-1), renin, aldosterone, Thromboxane B2 (TXB2) and 6-keto-prostaglandin F1α (PGF1α) before and at the end of VEGFI treatment without (treatment cycle 1) or with concomitant dietary sodium restriction (treatment cycle 2) in patients experiencing VEGFI-induced hypertension (intervention group).
| Treatment cycle 1 (VEGFI) | Treatment cycle 2 (VEGFI + dietary sodium restriction) | |||||||
|---|---|---|---|---|---|---|---|---|
| Start (visit 1) | End (visit 2) | P | Start (visit 3) | End (visit 4) | P | P visit 4 vs. visit 2 | P Δvisit 4−visit 3 vs. Δvisit 2−visit 1 | |
| Plasma | ||||||||
| ET-1, pg/ml | 2.1 (1.3–2.9) | 2.1 (1.7–3.6) | 0.63 | 1.7 (1.2–3.8) | 2.1 (1.4–3.3) | 0.30 | 0.21 | 0.95 |
| Renin, pg/ml | 14.4 (6.8–26.1) | 9.9 (5.9–30.7) | 0.76 | 23.3 (11.8–53.3) | 21.9 (13.5–51.6) | 0.60 | 0.13 | 0.98 |
| ET-1/renin ratio | 0.29 ± 0.1 | 0.39 ± 0.1 | 0.52 | 0.26 ± 0.1 | 0.17 ± 0.06 | 0.47 | 0.020 | 0.68 |
| Aldosterone, pg/ml | 259 (172–460) | 204 (168–420) | 0.56 | 332 (199–420) | 332 (226–612) | 0.45 | 0.018 | 0.45 |
| TXB2, pg/ml | 1351 (834–4062) | 1304 (567–2457) | 0.94 | 1740 (1175–2757) | 1744 (1082–3788) | 0.99 | 0.23 | 0.56 |
| 6-keto-PGF1α, pg/ml | 251 (182–414) | 585 (274–1098) | 0.025 | 355 (209–399) | 316 (252–620) | 0.32 | 0.056 | 0.055 |
| 24-h urine | ||||||||
| Sodium | 94 (77–135) | 44 (32–69) | 32 (24–49) | <0.001 | NA | |||
| Protein | 0.19 (0.11–0.32) | 0.16 (0.11–0.31) | 0.15 (0.10–0.25) | 0.0053 | NA | |||
Data are presented as median (IQR). P value indicates comparison between start and end of the same treatment cycle. P Δ indicates comparison of the within-cycle differences between treatment cycles 1 and 2.
VEGFI vascular endothelial growth factor inhibitor.